<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423071</url>
  </required_header>
  <id_info>
    <org_study_id>WI_PH+COPD_73/2011</org_study_id>
    <nct_id>NCT01423071</nct_id>
  </id_info>
  <brief_title>Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life</brief_title>
  <official_title>Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion Pharmaceuticals Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prevalence of pulmonary hypertension (PH) among
      patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and to assess the
      quality of life in those patients with concomitant PH compared to COPD patients without PH
      and those only suffering from pulmonary arterial hypertension (PAH) respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of PH</measure>
    <time_frame>At baseline</time_frame>
    <description>Prevalence of PH as defined by ESC/ERS guidelines (mean pulmonary arterial pressure ≥25 mmHg, assessed by right-heart catheterization) among the subgroup of COPD GOLD III and IV patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>One year</time_frame>
    <description>Explorative data analysis to assess correlation between quality of life and PH, by comparison of COPD patients with and without PH and a reference group of patients with only PAH.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">220</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>COPD with PH</arm_group_label>
    <description>COPD patients with confirmed diagnosis of PH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD without PH</arm_group_label>
    <description>COPD patients without confirmed diagnosis of PH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAH without COPD</arm_group_label>
    <description>PAH patients who do not suffer from COPD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        In- and out-patients at the investigational center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Known or newly diagnosed COPD or PAH

          -  Written informed consent

          -  Present long-term oxygen treatment is no exclusion criterion

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Right-heart catheterization not reasonable

          -  Pregnancy, Lactation

          -  Life expectancy &lt;12 months due to any diseases aside from COPD

          -  Any medical, psychological or other condition, which limits the patient's ability to
             provide informed consent

          -  No written informed consent provided

          -  Current participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried J Randerath, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wissenschaftliches Institut Bethanien e.V</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bethanien Hospital, Clinic for Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care, Institute for Pneumology at the University Witten/Herdecke</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008 Aug;32(2):503-12. doi: 10.1183/09031936.00160307. Review.</citation>
    <PMID>18669790</PMID>
  </reference>
  <reference>
    <citation>Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Jan;159(1):158-64.</citation>
    <PMID>9872834</PMID>
  </reference>
  <reference>
    <citation>Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995 May;107(5):1193-8.</citation>
    <PMID>7750305</PMID>
  </reference>
  <reference>
    <citation>Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003 May;21(5):892-905. Review.</citation>
    <PMID>12765440</PMID>
  </reference>
  <reference>
    <citation>Weitzenblum E. Chronic cor pulmonale. Heart. 2003 Feb;89(2):225-30. Review.</citation>
    <PMID>12527688</PMID>
  </reference>
  <reference>
    <citation>Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005 Jul 15;172(2):189-94. Epub 2005 Apr 14.</citation>
    <PMID>15831842</PMID>
  </reference>
  <reference>
    <citation>Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003 Mar 1;167(5):735-40. Epub 2002 Dec 12.</citation>
    <PMID>12480614</PMID>
  </reference>
  <reference>
    <citation>Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 1972 Apr 27;286(17):912-8.</citation>
    <PMID>5013974</PMID>
  </reference>
  <reference>
    <citation>Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981 Oct;36(10):752-8.</citation>
    <PMID>7330793</PMID>
  </reference>
  <reference>
    <citation>Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest. 1998 Mar;113(3):576-83.</citation>
    <PMID>9515827</PMID>
  </reference>
  <reference>
    <citation>Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S85-96. doi: 10.1016/j.jacc.2009.04.008. Review.</citation>
    <PMID>19555862</PMID>
  </reference>
  <reference>
    <citation>Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007 Nov;30(5):993-1013. Review.</citation>
    <PMID>17978157</PMID>
  </reference>
  <reference>
    <citation>Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J. 2006 Oct;28(4):808-15. Epub 2006 May 17.</citation>
    <PMID>16707511</PMID>
  </reference>
  <reference>
    <citation>Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):48S-55S. Review.</citation>
    <PMID>15194178</PMID>
  </reference>
  <reference>
    <citation>Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bossone E. Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest. 2009 Aug;136(2):597-603. doi: 10.1378/chest.08-1260. Review.</citation>
    <PMID>19666759</PMID>
  </reference>
  <reference>
    <citation>McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006 Feb;15(1):103-15.</citation>
    <PMID>16411035</PMID>
  </reference>
  <reference>
    <citation>McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes. 2008 Aug 21;6:65. doi: 10.1186/1477-7525-6-65.</citation>
    <PMID>18718016</PMID>
  </reference>
  <reference>
    <citation>Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J. 2008 Dec;32(6):1513-9. doi: 10.1183/09031936.00069708. Epub 2008 Sep 3.</citation>
    <PMID>18768576</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

